Search

Your search keyword '"Amaravadi, Ravi K."' showing total 704 results
Start Over Author "Amaravadi, Ravi K." Search Limiters Peer Reviewed
704 results on '"Amaravadi, Ravi K."'

1. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2024
Full Text
View/download PDF

2. Supplementary Table S3 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

3. Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

4. Data from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

5. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors

Author

Guan, Lei, Wu, Bin, Li, Ting, Beer, Lynn A., Sharma, Gaurav, Li, Mingyue, Lee, Chin Nien, Liu, Shujing, Yang, Changsong, Huang, Lili, Frederick, Dennie T., Boland, Genevieve M., Shao, Guangcan, Svitkina, Tatyana M., Cai, Kathy Q., Chen, Fangping, Dong, Meng-Qiu, Mills, Gordon B., Schuchter, Lynn M., Karakousis, Giorgos C., Mitchell, Tara C., Flaherty, Keith T., Speicher, David W., Chen, Youhai H., Herlyn, Meenhard, Amaravadi, Ravi K., Xu, Xiaowei, and Guo, Wei

Published
2022
Full Text
View/download PDF

6. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression

Author

Tameire, Feven, Verginadis, Ioannis I, Leli, Nektaria Maria, Polte, Christine, Conn, Crystal S, Ojha, Rani, Salas Salinas, Carlo, Chinga, Frank, Monroy, Alexandra M, Fu, Weixuan, Wang, Paul, Kossenkov, Andrew, Ye, Jiangbin, Amaravadi, Ravi K, Ignatova, Zoya, Fuchs, Serge Y, Diehl, J Alan, Ruggero, Davide, and Koumenis, Constantinos

Subjects
Biochemistry and Cell Biology, Biological Sciences, Genetics, Aetiology, 2.1 Biological and endogenous factors, Cancer, Activating Transcription Factor 4, Adaptor Proteins, Signal Transducing, Animals, Cell Cycle Proteins, Endoplasmic Reticulum Stress, Genes, myc, Humans, Mechanistic Target of Rapamycin Complex 1, Mice, Transgenic, Phosphoproteins, Phosphorylation, Protein Biosynthesis, TOR Serine-Threonine Kinases, Transcriptional Activation, Medical and Health Sciences, Developmental Biology, Biochemistry and cell biology
Abstract

The c-Myc oncogene drives malignant progression and induces robust anabolic and proliferative programmes leading to intrinsic stress. The mechanisms enabling adaptation to MYC-induced stress are not fully understood. Here we reveal an essential role for activating transcription factor 4 (ATF4) in survival following MYC activation. MYC upregulates ATF4 by activating general control nonderepressible 2 (GCN2) kinase through uncharged transfer RNAs. Subsequently, ATF4 co-occupies promoter regions of over 30 MYC-target genes, primarily those regulating amino acid and protein synthesis, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), a negative regulator of translation. 4E-BP1 relieves MYC-induced proteotoxic stress and is essential to balance protein synthesis. 4E-BP1 activity is negatively regulated by mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation and inhibition of mTORC1 signalling rescues ATF4-deficient cells from MYC-induced endoplasmic reticulum stress. Acute deletion of ATF4 significantly delays MYC-driven tumour progression and increases survival in mouse models. Our results establish ATF4 as a cellular rheostat of MYC activity, which ensures that enhanced translation rates are compatible with survival and tumour progression.

Published
2019

7. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Author

Kugel, Curtis H, Douglass, Stephen M, Webster, Marie R, Kaur, Amanpreet, Liu, Qin, Yin, Xiangfan, Weiss, Sarah A, Darvishian, Farbod, Al-Rohil, Rami N, Ndoye, Abibatou, Behera, Reeti, Alicea, Gretchen M, Ecker, Brett L, Fane, Mitchell, Allegrezza, Michael J, Svoronos, Nikolaos, Kumar, Vinit, Wang, Daniel Y, Somasundaram, Rajasekharan, Hu-Lieskovan, Siwen, Ozgun, Alpaslan, Herlyn, Meenhard, Conejo-Garcia, Jose R, Gabrilovich, Dmitry, Stone, Erica L, Nowicki, Theodore S, Sosman, Jeffrey, Rai, Rajat, Carlino, Matteo S, Long, Georgina V, Marais, Richard, Ribas, Antoni, Eroglu, Zeynep, Davies, Michael A, Schilling, Bastian, Schadendorf, Dirk, Xu, Wei, Amaravadi, Ravi K, Menzies, Alexander M, McQuade, Jennifer L, Johnson, Douglas B, Osman, Iman, and Weeraratna, Ashani T

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Vaccine Related, Immunization, Aging, 2.1 Biological and endogenous factors, Aetiology, Age Factors, Animals, Antineoplastic Agents, Immunological, Biomarkers, Tumor, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Immunomodulation, Melanoma, Mice, Mice, Transgenic, Neoplasms, Programmed Cell Death 1 Receptor, T-Lymphocytes, Regulatory, Tumor Microenvironment, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1.Experimental Design: We analyzed the relationship between age, response to anti-PD1, and prior therapy in 538 patients. We used mouse models of melanoma, to analyze the intratumoral immune microenvironment in young versus aged mice and confirmed our findings in human melanoma biopsies.Results: Patients over the age of 60 responded more efficiently to anti-PD-1, and likelihood of response to anti-PD-1 increased with age, even when we controlled for prior MAPKi therapy. Placing genetically identical tumors in aged mice (52 weeks) significantly increased their response to anti-PD1 as compared with the same tumors in young mice (8 weeks). These data suggest that this increased response in aged patients occurs even in the absence of a more complex mutational landscape. Next, we found that young mice had a significantly higher population of regulatory T cells (Tregs), skewing the CD8+:Treg ratio. FOXP3 staining of human melanoma biopsies revealed similar increases in Tregs in young patients. Depletion of Tregs using anti-CD25 increased the response to anti-PD1 in young mice.Conclusions: While there are obvious limitations to our study, including our inability to conduct a meta-analysis due to a lack of available data, and our inability to control for mutational burden, there is a remarkable consistency in these data from over 500 patients across 8 different institutes worldwide. These results stress the importance of considering age as a factor for immunotherapy response. Clin Cancer Res; 24(21); 5347-56. ©2018 AACR See related commentary by Pawelec, p. 5193.

Published
2018

8. Lysosomal lipid peroxidation regulates tumor immunity

Author

Bhardwaj, Monika, Lee, Jennifer J., Versace, Amanda M., Harper, Sandra L., Goldman, Aaron R., Crissey, Mary Ann S., Jain, Vaibhav, Singh, Mahendra Pal, Vernon, Megane, Aplin, Andrew E., Lee, Seokwoo, Morita, Masao, Winkler, Jeffrey D., Liu, Qin, Speicher, David W., and Amaravadi, Ravi K.

Subjects
Oncology, Experimental, Lipid peroxidation -- Research, Cell death -- Research, Tumors -- Development and progression, Immunity -- Research, Cancer -- Research, Lysosomes -- Physiological aspects -- Health aspects, Health care industry
Abstract

Lysosomal inhibition elicited by palmitoyl-protein thioesterase 1 (PPT1) inhibitors such as DC661 can produce cell death, but the mechanism for this is not completely understood. Programmed cell death pathways (autophagy, apoptosis, necroptosis, ferroptosis, and pyroptosis) were not required to achieve the cytotoxic effect of DC661. Inhibition of cathepsins, or iron or calcium chelation, did not rescue DC661-induced cytotoxicity. PPT1 inhibition induced lysosomal lipid peroxidation (LLP), which led to lysosomal membrane permeabilization and cell death that could be reversed by the antioxidant N-acetylcysteine (NAC) but not by other lipid peroxidation antioxidants. The lysosomal cysteine transporter MFSD12 was required for intralysosomal transport of NAC and rescue of LLP. PPT1 inhibition produced cell-intrinsic immunogenicity with surface expression of calreticulin that could only be reversed with NAC. DC661-treated cells primed naive T cells and enhanced T cell-mediated toxicity. Mice vaccinated with DC661-treated cells engendered adaptive immunity and tumor rejection in 'immune hot' tumors but not in 'immune cold' tumors. These findings demonstrate that LLP drives lysosomal cell death, a unique immunogenic form of cell death, pointing the way to rational combinations of immunotherapy and lysosomal inhibition that can be tested in clinical trials., Introduction With encouraging activity in clinical trials that involve the lysosomal inhibitor hydroxychloroquine (HCQ) (1), the identification of palmitoyl-protein thioesterase 1 (PPT1) as the molecular target of chloroquine derivatives (2), [...]

Published
2023
Full Text
View/download PDF

9. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., additional, Huang, Alexander C., additional, Xu, Xiaowei, additional, Yoon, Daniel, additional, Shang, Catherine G., additional, Mick, Rosemarie, additional, Schubert, Erin, additional, McGettigan, Suzanne, additional, Kreider, Kristin, additional, Xu, Wei, additional, Wherry, E. John, additional, Schuchter, Lynn M., additional, Amaravadi, Ravi K., additional, Mitchell, Tara C., additional, and Farwell, Michael D., additional

Published
2024
Full Text
View/download PDF

10. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

11. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

12. 579-C Reinvigoration of progenitor-exhausted CD8 T cells by anti-CTLA-4 contributes to the sustained activity of combination checkpoint blockade

Author

Wang, Kevin, primary, Coutifaris, Paulina, additional, Brocks, David, additional, Solis, Sabrina, additional, Han, Nicholas, additional, Manne, Sasikanth, additional, Kiner, Evgeny, additional, Sachar, Chirag, additional, George, Sangeeth, additional, Yan, Patrick, additional, Kiner, Melanie W, additional, Laughlin, Amy I, additional, Kothari, Shawn, additional, Giles, Josephine R, additional, Mathew, Divij, additional, Ghinnagow, Rheem, additional, Alanio, Cecile, additional, Flowers, Ahron, additional, Xu, Wei, additional, Tenney, Daniel, additional, Xu, Xiaowei, additional, Amaravadi, Ravi K, additional, Karakousis, Giorgos C, additional, Schuchter, Lynn M, additional, Buggert, Marcus, additional, John Wherry, E, additional, Minn, Andy, additional, Weber, Jeffrey, additional, Mitchell, Tara, additional, Herati, Ramin S, additional, and Huang, Alexander, additional

Published
2023
Full Text
View/download PDF

14. Long-term outcome in BRAF V600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

Author

Puzanov, Igor, Amaravadi, Ravi K, McArthur, Grant A, Flaherty, Keith T, Chapman, Paul B, Sosman, Jeffrey A, Ribas, Antoni, Shackleton, Mark, Hwu, Patrick, Chmielowski, Bartosz, Nolop, Keith B, Lin, Paul S, and Kim, Kevin B

Subjects
Cancer, Brain Disorders, Clinical Trials and Supportive Activities, Clinical Research, Adult, Aged, Aged, 80 and over, Disease Progression, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Sulfonamides, Survival Rate, Vemurafenib, Young Adult, BRAF inhibitor, Metastatic melanoma, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

IntroductionVemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF(V600E) melanoma treated in the phase 1 vemurafenib trial is reported.MethodsPatients received vemurafenib 240-1120 mg (dose escalation cohort) or 960 mg (extension cohort) orally twice daily. Clinical response was evaluated every 8 weeks by Response Evaluation Criteria In Solid Tumors (RECIST). Patients with PD amenable to local therapy (surgery or radiotherapy) were allowed to continue vemurafenib after progression. Overall survival (OS) from time of treatment initiation and from PD was estimated. Sites of PD were recorded.ResultsForty-eight patients (escalation cohort, n = 16; extension cohort, n = 32) received therapeutic doses of vemurafenib (⩾ 240 mg twice daily). Forty-four patients had PD by the time of this analysis and four remained progression free (follow-up time, 1.2-56.1 months). Median OS was 14 months (range, 1.2-56.1); 3- and 4-year melanoma-specific survival rate in the extension cohort was 26% and 19%, respectively. Median OS was 26.0 months (range, 7.7-56.1) among 20 patients who continued vemurafenib after local therapy. Median treatment duration beyond initial PD was 3.8 months (range, 1.1-26.6). In the extension cohort, six and five patients were alive after 3 and 4 years, respectively, on vemurafenib monotherapy.ConclusionsSome patients with melanoma achieved long-term survival with vemurafenib monotherapy. Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease might continue to respond to BRAF inhibition.

Published
2015

15. Autophagy in malignant transformation and cancer progression

Author

Galluzzi, Lorenzo, Pietrocola, Federico, Bravo-San Pedro, José Manuel, Amaravadi, Ravi K, Baehrecke, Eric H, Cecconi, Francesco, Codogno, Patrice, Debnath, Jayanta, Gewirtz, David A, Karantza, Vassiliki, Kimmelman, Alec, Kumar, Sharad, Levine, Beth, Maiuri, Maria Chiara, Martin, Seamus J, Penninger, Josef, Piacentini, Mauro, Rubinsztein, David C, Simon, Hans-Uwe, Simonsen, Anne, Thorburn, Andrew M, Velasco, Guillermo, Ryan, Kevin M, and Kroemer, Guido

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Brain Disorders, Rare Diseases, Brain Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Autophagy, Cell Transformation, Neoplastic, Humans, Neoplasms, Tumor Escape, Tumor Suppressor Proteins, adaptive stress responses, Beclin 1, inflammation, KRAS, mitophagy, Biological Sciences, Information and Computing Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells, such a homeostatic activity constitutes a robust barrier against malignant transformation. Accordingly, many oncoproteins inhibit, and several oncosuppressor proteins promote, autophagy. Moreover, autophagy is required for optimal anticancer immunosurveillance. In neoplastic cells, however, autophagic responses constitute a means to cope with intracellular and environmental stress, thus favoring tumor progression. This implies that at least in some cases, oncogenesis proceeds along with a temporary inhibition of autophagy or a gain of molecular functions that antagonize its oncosuppressive activity. Here, we discuss the differential impact of autophagy on distinct phases of tumorigenesis and the implications of this concept for the use of autophagy modulators in cancer therapy.

Published
2015

17. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma

Author

Barnard, Rebecca A, Wittenburg, Luke A, Amaravadi, Ravi K, Gustafson, Daniel L, Thorburn, Andrew, and Thamm, Douglas H

Subjects
Cancer, Lymphoma, Orphan Drug, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Animals, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Dogs, Dose-Response Relationship, Drug, Doxorubicin, Female, Hydroxychloroquine, Male, Pets, Treatment Outcome, autophagy, lymphoma, canine model, hydroxychloroquine, doxorubicin, Biochemistry and Cell Biology, Biochemistry & Molecular Biology
Abstract

Autophagy is a lysosomal degradation process that may act as a mechanism of survival in a variety of cancers. While pharmacologic inhibition of autophagy with hydroxychloroquine (HCQ) is currently being explored in human clinical trials, it has never been evaluated in canine cancers. Non-Hodgkin lymphoma (NHL) is one of the most prevalent tumor types in dogs and has similar pathogenesis and response to treatment as human NHL. Clinical trials in canine patients are conducted in the same way as in human patients, thus, to determine a maximum dose of HCQ that can be combined with a standard chemotherapy, a Phase I, single arm, dose escalation trial was conducted in dogs with spontaneous NHL presenting as patients to an academic, tertiary-care veterinary teaching hospital. HCQ was administered daily by mouth throughout the trial, beginning 72 h prior to doxorubicin (DOX), which was given intravenously on a 21-d cycle. Peripheral blood mononuclear cells and biopsies were collected before and 3 d after HCQ treatment and assessed for autophagy inhibition and HCQ concentration. A total of 30 patients were enrolled in the trial. HCQ alone was well tolerated with only mild lethargy and gastrointestinal-related adverse events. The overall response rate (ORR) for dogs with lymphoma was 93.3%, with median progression-free interval (PFI) of 5 mo. Pharmacokinetic analysis revealed a 100-fold increase in HCQ in tumors compared with plasma. There was a trend that supported therapy-induced increase in LC3-II (the cleaved and lipidated form of microtubule-associated protein 1 light chain 3/LC3, which serves as a maker for autophagosomes) and SQSTM1/p62 (sequestosome 1) after treatment. The superior ORR and comparable PFI to single-agent DOX provide strong support for further evaluation via randomized, placebo-controlled trials in canine and human NHL.

Published
2014

19. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Author

Khan, Omar, Giles, Josephine R., McDonald, Sierra, Manne, Sasikanth, Ngiow, Shin Foong, Patel, Kunal P., Werner, Michael T., Huang, Alexander C., Alexander, Katherine A., Wu, Jennifer E., Attanasio, John, Yan, Patrick, George, Sangeeth M., Bengsch, Bertram, Staupe, Ryan P., Donahue, Greg, Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Kaye, Jonathan, Berger, Shelley L., and Wherry, E. John

Published
2019
Full Text
View/download PDF

20. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors

Author

Baquero, Pablo, Dawson, Amy, Mukhopadhyay, Arunima, Kuntz, Elodie M., Mitchell, Rebecca, Olivares, Orianne, Ianniciello, Angela, Scott, Mary T., Dunn, Karen, Nicastri, Michael C., Winkler, Jeffrey D., Michie, Alison M., Ryan, Kevin M., Halsey, Christina, Gottlieb, Eyal, Keaney, Erin P., Murphy, Leon O., Amaravadi, Ravi K., Holyoake, Tessa L., and Helgason, G. Vignir

Published
2019
Full Text
View/download PDF

21. TABLE 3 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

24. FIGURE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

25. TABLE 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

26. TABLE 4 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

27. TABLE 5 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

28. TABLE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

29. FIGURE 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

30. Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma

Author

Shah, Payal D., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P., primary, Brennan, Andrea, primary, Gonzalez, Vanessa, primary, Kulikovskaya, Irina, primary, Lacey, Simon F., primary, Plesa, Gabriela, primary, June, Carl H., primary, Vonderheide, Robert H., primary, and Mitchell, Tara C., primary

Published
2023
Full Text
View/download PDF

32. Data from Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition

Author

Jain, Vaibhav, primary, Harper, Sandra L., primary, Versace, Amanda M., primary, Fingerman, Dylan, primary, Brown, Gregory Schuyler, primary, Bhardwaj, Monika, primary, Crissey, Mary Ann S., primary, Goldman, Aaron R., primary, Ruthel, Gordon, primary, Liu, Qin, primary, Zivkovic, Aleksandra, primary, Stark, Holgar, primary, Herlyn, Meenhard, primary, Gimotty, Phyllis A., primary, Speicher, David W., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Data Figures S1-S5 from Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition

Author

Jain, Vaibhav, primary, Harper, Sandra L., primary, Versace, Amanda M., primary, Fingerman, Dylan, primary, Brown, Gregory Schuyler, primary, Bhardwaj, Monika, primary, Crissey, Mary Ann S., primary, Goldman, Aaron R., primary, Ruthel, Gordon, primary, Liu, Qin, primary, Zivkovic, Aleksandra, primary, Stark, Holgar, primary, Herlyn, Meenhard, primary, Gimotty, Phyllis A., primary, Speicher, David W., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data Tables S1-S2 from Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition

Author

Jain, Vaibhav, primary, Harper, Sandra L., primary, Versace, Amanda M., primary, Fingerman, Dylan, primary, Brown, Gregory Schuyler, primary, Bhardwaj, Monika, primary, Crissey, Mary Ann S., primary, Goldman, Aaron R., primary, Ruthel, Gordon, primary, Liu, Qin, primary, Zivkovic, Aleksandra, primary, Stark, Holgar, primary, Herlyn, Meenhard, primary, Gimotty, Phyllis A., primary, Speicher, David W., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 2 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma

Author

Shah, Payal D, primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K, primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P, primary, Brennan, Andrea Lynne, primary, Gonzalez, Vanessa E, primary, Kulikovskaya, Irina, primary, Lacey, Simon F, primary, Plesa, Gabriela, primary, June, Carl H, primary, Vonderheide, Robert H, primary, and Mitchell, Tara C, primary

Published
2023
Full Text
View/download PDF

36. Data from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Author

Ojha, Rani, primary, Leli, Nektaria M., primary, Onorati, Angelique, primary, Piao, Shengfu, primary, Verginadis, Ioannis I., primary, Tameire, Feven, primary, Rebecca, Vito W., primary, Chude, Cynthia I., primary, Murugan, Sengottuvelan, primary, Fennelly, Colin, primary, Noguera-Ortega, Estela, primary, Chu, Charleen T., primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Krepler, Clemens, primary, Xiao, Min, primary, Xu, Wei, primary, Wei, Zhi, primary, Frederick, Dennie T., primary, Boland, Genevieve, primary, Mitchell, Tara C., primary, Karakousis, Giorgos C., primary, Schuchter, Lynn M., primary, Flaherty, Keith T., primary, Zhang, Gao, primary, Herlyn, Meenhard, primary, Koumenis, Constantinos, primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S6 from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

Author

O'Connell, Michael P., primary, Marchbank, Katie, primary, Webster, Marie R., primary, Valiga, Alexander A., primary, Kaur, Amanpreet, primary, Vultur, Adina, primary, Li, Ling, primary, Herlyn, Meenhard, primary, Villanueva, Jessie, primary, Liu, Qin, primary, Yin, Xiangfan, primary, Widura, Sandy, primary, Nelson, Janelle, primary, Ruiz, Nivia, primary, Camilli, Tura C., primary, Indig, Fred E., primary, Flaherty, Keith T., primary, Wargo, Jennifer A., primary, Frederick, Dennie T., primary, Cooper, Zachary A., primary, Nair, Suresh, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Karakousis, Giorgos C., primary, Xu, Wei, primary, Xu, Xiaowei, primary, and Weeraratna, Ashani T., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma

Author

Shah, Payal D, primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K, primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P, primary, Brennan, Andrea Lynne, primary, Gonzalez, Vanessa E, primary, Kulikovskaya, Irina, primary, Lacey, Simon F, primary, Plesa, Gabriela, primary, June, Carl H, primary, Vonderheide, Robert H, primary, and Mitchell, Tara C, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure Legends from Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Author

Sanseviero, Emilio, primary, O’Brien, Erin M., primary, Karras, Jenna R., primary, Shabaneh, Tamer B., primary, Aksoy, Bulent Arman, primary, Xu, Wei, primary, Zheng, Cathy, primary, Yin, Xiangfan, primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Amaravadi, Ravi K., primary, Nam, Brian, primary, Turk, Mary Jo, primary, Hammerbacher, Jeff, primary, Rubinstein, Mark P., primary, Schuchter, Lynn M., primary, Mitchell, Tara C., primary, Liu, Qin, primary, and Stone, Erica L., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Author

Ojha, Rani, primary, Leli, Nektaria M., primary, Onorati, Angelique, primary, Piao, Shengfu, primary, Verginadis, Ioannis I., primary, Tameire, Feven, primary, Rebecca, Vito W., primary, Chude, Cynthia I., primary, Murugan, Sengottuvelan, primary, Fennelly, Colin, primary, Noguera-Ortega, Estela, primary, Chu, Charleen T., primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Krepler, Clemens, primary, Xiao, Min, primary, Xu, Wei, primary, Wei, Zhi, primary, Frederick, Dennie T., primary, Boland, Genevieve, primary, Mitchell, Tara C., primary, Karakousis, Giorgos C., primary, Schuchter, Lynn M., primary, Flaherty, Keith T., primary, Zhang, Gao, primary, Herlyn, Meenhard, primary, Koumenis, Constantinos, primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

41. Data from Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma

Author

Shah, Payal D, primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Orlowski, Robert, primary, Amaravadi, Ravi K, primary, Schuchter, Lynn M., primary, Zhang, Paul, primary, Tchou, Julia, primary, Matlawski, Tina, primary, Cervini, Amanda, primary, Shea, Joanne, primary, Gilmore, Joan, primary, Lledo, Lester, primary, Dengel, Karen, primary, Marshall, Amy, primary, Wherry, E. John, primary, Linette, Gerald P, primary, Brennan, Andrea Lynne, primary, Gonzalez, Vanessa E, primary, Kulikovskaya, Irina, primary, Lacey, Simon F, primary, Plesa, Gabriela, primary, June, Carl H, primary, Vonderheide, Robert H, primary, and Mitchell, Tara C, primary

Published
2023
Full Text
View/download PDF

42. Supplemental Figures S1-S7 and Supplemental Table S1 from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Author

Rebecca, Vito W., primary, Nicastri, Michael C., primary, McLaughlin, Noel, primary, Fennelly, Colin, primary, McAfee, Quentin, primary, Ronghe, Amruta, primary, Nofal, Michel, primary, Lim, Chun-Yan, primary, Witze, Eric, primary, Chude, Cynthia I., primary, Zhang, Gao, primary, Alicea, Gretchen M., primary, Piao, Shengfu, primary, Murugan, Sengottuvelan, primary, Ojha, Rani, primary, Levi, Samuel M., primary, Wei, Zhi, primary, Barber-Rotenberg, Julie S., primary, Murphy, Maureen E., primary, Mills, Gordon B., primary, Lu, Yiling, primary, Rabinowitz, Joshua, primary, Marmorstein, Ronen, primary, Liu, Qin, primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Herlyn, Meenhard, primary, Zoncu, Roberto, primary, Brady, Donita C., primary, Speicher, David W., primary, Winkler, Jeffrey D., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figures S1-S4 from PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer

Author

Rebecca, Vito W., primary, Nicastri, Michael C., primary, Fennelly, Colin, primary, Chude, Cynthia I., primary, Barber-Rotenberg, Julie S., primary, Ronghe, Amruta, primary, McAfee, Quentin, primary, McLaughlin, Noel P., primary, Zhang, Gao, primary, Goldman, Aaron R., primary, Ojha, Rani, primary, Piao, Shengfu, primary, Noguera-Ortega, Estela, primary, Martorella, Alessandra, primary, Alicea, Gretchen M., primary, Lee, Jennifer J., primary, Schuchter, Lynn M., primary, Xu, Xiaowei, primary, Herlyn, Meenhard, primary, Marmorstein, Ronen, primary, Gimotty, Phyllis A., primary, Speicher, David W., primary, Winkler, Jeffrey D., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

44. Data from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Author

Rebecca, Vito W., primary, Nicastri, Michael C., primary, McLaughlin, Noel, primary, Fennelly, Colin, primary, McAfee, Quentin, primary, Ronghe, Amruta, primary, Nofal, Michel, primary, Lim, Chun-Yan, primary, Witze, Eric, primary, Chude, Cynthia I., primary, Zhang, Gao, primary, Alicea, Gretchen M., primary, Piao, Shengfu, primary, Murugan, Sengottuvelan, primary, Ojha, Rani, primary, Levi, Samuel M., primary, Wei, Zhi, primary, Barber-Rotenberg, Julie S., primary, Murphy, Maureen E., primary, Mills, Gordon B., primary, Lu, Yiling, primary, Rabinowitz, Joshua, primary, Marmorstein, Ronen, primary, Liu, Qin, primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Herlyn, Meenhard, primary, Zoncu, Roberto, primary, Brady, Donita C., primary, Speicher, David W., primary, Winkler, Jeffrey D., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 1 from Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Author

Sanseviero, Emilio, primary, O’Brien, Erin M., primary, Karras, Jenna R., primary, Shabaneh, Tamer B., primary, Aksoy, Bulent Arman, primary, Xu, Wei, primary, Zheng, Cathy, primary, Yin, Xiangfan, primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Amaravadi, Ravi K., primary, Nam, Brian, primary, Turk, Mary Jo, primary, Hammerbacher, Jeff, primary, Rubinstein, Mark P., primary, Schuchter, Lynn M., primary, Mitchell, Tara C., primary, Liu, Qin, primary, and Stone, Erica L., primary

Published
2023
Full Text
View/download PDF

46. Data from Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Author

Sanseviero, Emilio, primary, O’Brien, Erin M., primary, Karras, Jenna R., primary, Shabaneh, Tamer B., primary, Aksoy, Bulent Arman, primary, Xu, Wei, primary, Zheng, Cathy, primary, Yin, Xiangfan, primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Amaravadi, Ravi K., primary, Nam, Brian, primary, Turk, Mary Jo, primary, Hammerbacher, Jeff, primary, Rubinstein, Mark P., primary, Schuchter, Lynn M., primary, Mitchell, Tara C., primary, Liu, Qin, primary, and Stone, Erica L., primary

Published
2023
Full Text
View/download PDF

47. Chemical Methods from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

Author

Rebecca, Vito W., primary, Nicastri, Michael C., primary, McLaughlin, Noel, primary, Fennelly, Colin, primary, McAfee, Quentin, primary, Ronghe, Amruta, primary, Nofal, Michel, primary, Lim, Chun-Yan, primary, Witze, Eric, primary, Chude, Cynthia I., primary, Zhang, Gao, primary, Alicea, Gretchen M., primary, Piao, Shengfu, primary, Murugan, Sengottuvelan, primary, Ojha, Rani, primary, Levi, Samuel M., primary, Wei, Zhi, primary, Barber-Rotenberg, Julie S., primary, Murphy, Maureen E., primary, Mills, Gordon B., primary, Lu, Yiling, primary, Rabinowitz, Joshua, primary, Marmorstein, Ronen, primary, Liu, Qin, primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Herlyn, Meenhard, primary, Zoncu, Roberto, primary, Brady, Donita C., primary, Speicher, David W., primary, Winkler, Jeffrey D., primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

48. Data from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

Author

O'Connell, Michael P., primary, Marchbank, Katie, primary, Webster, Marie R., primary, Valiga, Alexander A., primary, Kaur, Amanpreet, primary, Vultur, Adina, primary, Li, Ling, primary, Herlyn, Meenhard, primary, Villanueva, Jessie, primary, Liu, Qin, primary, Yin, Xiangfan, primary, Widura, Sandy, primary, Nelson, Janelle, primary, Ruiz, Nivia, primary, Camilli, Tura C., primary, Indig, Fred E., primary, Flaherty, Keith T., primary, Wargo, Jennifer A., primary, Frederick, Dennie T., primary, Cooper, Zachary A., primary, Nair, Suresh, primary, Amaravadi, Ravi K., primary, Schuchter, Lynn M., primary, Karakousis, Giorgos C., primary, Xu, Wei, primary, Xu, Xiaowei, primary, and Weeraratna, Ashani T., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Author

Sanseviero, Emilio, primary, O’Brien, Erin M., primary, Karras, Jenna R., primary, Shabaneh, Tamer B., primary, Aksoy, Bulent Arman, primary, Xu, Wei, primary, Zheng, Cathy, primary, Yin, Xiangfan, primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Amaravadi, Ravi K., primary, Nam, Brian, primary, Turk, Mary Jo, primary, Hammerbacher, Jeff, primary, Rubinstein, Mark P., primary, Schuchter, Lynn M., primary, Mitchell, Tara C., primary, Liu, Qin, primary, and Stone, Erica L., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Movie 1 from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Author

Ojha, Rani, primary, Leli, Nektaria M., primary, Onorati, Angelique, primary, Piao, Shengfu, primary, Verginadis, Ioannis I., primary, Tameire, Feven, primary, Rebecca, Vito W., primary, Chude, Cynthia I., primary, Murugan, Sengottuvelan, primary, Fennelly, Colin, primary, Noguera-Ortega, Estela, primary, Chu, Charleen T., primary, Liu, Shujing, primary, Xu, Xiaowei, primary, Krepler, Clemens, primary, Xiao, Min, primary, Xu, Wei, primary, Wei, Zhi, primary, Frederick, Dennie T., primary, Boland, Genevieve, primary, Mitchell, Tara C., primary, Karakousis, Giorgos C., primary, Schuchter, Lynn M., primary, Flaherty, Keith T., primary, Zhang, Gao, primary, Herlyn, Meenhard, primary, Koumenis, Constantinos, primary, and Amaravadi, Ravi K., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results